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RESEARCH ARTICLE Open Access
Single-fiber electromyography in the
orbicularis oculi muscle in patients with
ocular myasthenia gravis symptoms: does
abnormal jitter predict response to
treatment?
Goran Rakocevic1*, Mark Moster2 and Mary Kay Floeter3
Abstract
Background: Seronegative ocular myasthenia gravis (OMG) is diagnosed by ocular symptoms with supporting
SFEMG, typically of frontalis or extensor digitorum muscles. We aimed to determine the sensitivity and specificity of
orbicularis oculi SFEMG to diagnose and exclude myasthenia gravis and predict response to therapy.
Methods: Orbicularis oculi SFEMG studies were conducted in 142 consecutive patients with symptoms and/or
findings of OMG and negative AChR antibody during the period of 5 years. Retrospective chart review was
conducted 2 years after the SFEMG to determine whether treatments were given and responses to treatment.
Results: Orbicularis oculi SFEMG was abnormal in 31 patients and normal in 111 patients. Twenty-nine patients
with abnormal SFEMG were treated, and 25 had a good response. Twenty-four patients with normal SFEMG
received treatment; none responded to treatment or developed generalized myasthenia.
Conclusion: An abnormal orbicularis oculi SFEMG in patients with seronegative OMG has a high predictive value
for response to therapy. Our study findings may affect the treatment decisions in practice and aid better
management of myasthenic patients.
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Background
SFEMG is the most sensitive diagnostic test for diagnosis
of seronegative myasthenia gravis [1–3]. Frontalis, orbicu-
laris oculi and extensor digitorum communis (EDC) are
commonly tested muscles in the electrophysiological
exam. There are no current guidelines to apply when
deciding what and how many muscles to evaluate in order
to increase the yield of diagnostic sensitivity and specifi-
city. Based on several studies comparing SFEMG of fron-
talis and or EDC muscles with repetitive nerve stimulation
(RNS) [4–6], SFEMG is established as more sensitive test
for diagnosing NMJ disorder than RNS. More recent
studies investigated the utility of SFEMG in orbicularis
oculi muscles in diagnosing MG. These studies, carried
out on a mixed population of patients with focal or gener-
alized myasthenic symptoms, found that SFEMG of the
orbicularis oculi was reliable for diagnosis of MG [7] and
had prognostic value for predicting the severity of
patients’ clinical course [8]. We postulated that SFEMG in
orbicularis oculi muscle would be particularly relevant for
diagnosis and predicting response to therapy in a cohort
of seronegative patients with typical visual symptoms of
ocular myasthenia.
Methods
Eighty-six women and fifty-six men with negative AChR
antibody and fluctuating ocular symptoms (double vision
in 79, ptosis in 37, and both in 51 patients) were referred
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for evaluation of ocular myasthenia gravis. The clinical
diagnosis of ocular myasthenia (OMG) was based on
the presence of at least one of cardinal visual symptom
(diplopia) and/or findings on exam (variable extraocular
muscle weakness and ptosis) by two examiners: a referring
neuro-ophthalmologist and examining neurologist. All
patients had ocular symptoms and/or findings for at least
one month prior to SFEMG. Three patients were adoles-
cents of 15, 16 and 17 years of age. A complete neuro-
ophthalmologic evaluation including an MRI of brain with
orbital protocol was performed in all patients to exclude
other neurological disorders. All patients had laboratory
testing for serum AchR and six were tested for anti-
MuSK antibody. No patients had undergone genetic
testing for other possible causes of external ophthalmo-
plegia prior to SFEMG, and during the follow up period
after electrophysiological study.
SFEMG in orbicularis oculi muscle was intended as
the measured variable, while the clinical criterion used
as the gold standard was objective eyelid and/ or orbicu-
laris oculi and extraocular muscle weakness on exam
with fluctuating symptoms and findings.
SFEMG was performed on both orbicularis oculi mus-
cles in all patients by the same examining neurologist in
a single center (GR), using a SFEMG needle with standard
techniques. A minimum of twenty pairs of muscle fibers
were recorded from right and left orbicularis oculi muscle
from all patients. The SFEMG study was considered
abnormal: 1) if the mean jitter (MCD) in twenty pairs
exceeded normal values for the orbicularis oculi and the
patient’s age [7, 9]; or 2) if >10% of all studied pairs had
jitter above the maximum allowed for a single pair using
values adjusted for age.
Following the SFEMG study, treatment decisions were
determined by referring physicians. Two-year follow up
information for all patients was acquired by chart
review, phone contact and office examination. The deter-
mination of generalized MG was based on development of
symptomatic bulbar and/ or limb weakness confirmed by
clinical examination by referring or treating neurologist.
The medical charts were reviewed and patients’ symptoms
and response to therapy, if any, were documented during
a 2-year follow-up period. The determination about a
therapeutic response and whether generalized myasthenia
(GMG) developed were based on the examinations by
neuro-ophthalmologists and treating neurologists in the
clinic and documented in the medical records or by a tele-
phone interview.
T-tests were used to compare demographic data of
patients with normal SFEMG to those with abnormal
SFEMG, with p < 0.05 as threshold for significance. A
positive response to therapy was defined as objective
improvement of symptoms and findings on exam. The
relationship between a positive response and an abnormal
SFEMG was calculated using Fisher’s exact test. The sensi-
tivity and specificity of orbicularis oculi muscle SFEMG to
predict treatment-responsive OMG and development of
generalized MG were also calculated. Statistics were car-
ried out in Prism 6 (www.graphpad.com).
Results
One hundred and eleven patients had normal jitter and
thirty-one had abnormal jitter. There was no significant
difference in the mean age or disease duration of the
two groups. Gender was equal in the group with abnor-
mal jitter. Women made up 63% of the patients in the
group with normal jitter.
Twenty-nine of 31 patients with abnormal jitter
received treatment: pyridostigmine first, and if favorable
but suboptimal response, by adding prednisone until
resolution of symptoms. Two were not treated and 1
patient’s follow-up information was missing.
Twenty-five patients had a positive response to treat-
ment as defined by improvement of ocular symptoms
and signs, and based on objective neurologic or ophthal-
mologic exam (Table 1). In the group of patients with
normal jitter, 24 patients were treated and 87 patients
were not treated. Pyridostigmine alone and/or combined
with oral steroids did not provide benefit in non-
responders regardless of an underlying etiology, which
was not conclusively established for each non-responder.
More women than men with normal jitter were treated.
This difference in treatment by gender was significant.
None of the treated patients with normal jitter had a
positive response to treatment. Thus, abnormal jitter
was significantly associated with a beneficial response
to treatment (Fisher exact test p < 0.001). Abnormal
jitter had 100% sensitivity and 85.7% specificity for
response to therapy. The positive predictive value was
86.2% and negative predictive value was 100% for
response to treatment.
Four patients with negative MuSK antibody were given
pyridostigmine trial with no benefit. Another patient
was later found to have MuSK antibodies after a normal
SFEMG, but did not receive any myasthenic therapy due
to intercurrent cancer. A single patient who presented
with ocular symptoms and had an abnormal SFEMG
eventually developed generalized myasthenia.
Table 1 Response to MG therapy and SFEMG findings in
patients with fluctuating ocular symptoms
Data analyzed No response Responded Total
Group with abnormal jitter 4 25 29
Group with normal jitter 24 0 24
Total 28 25 53
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Discussion
This study confirms usefulness of SFEMG for detecting
a NMJ disorder in patients with fluctuating extraocular
muscle weakness and negative antibodies by recording
SFEMG from orbicularis oculi muscles. Additionally, we
have shown that abnormal jitter in orbicularis oculi mus-
cles in patients presenting with a clinical picture of ocular
myasthenia correlated with response to myasthenic ther-
apies. The sensitivity and specificity of SFEMG was studied
in this patient cohort retrospectively and correlated with
their response to myasthenic therapy, if administered by
referring physicians. An abnormal SFEMG was not pre-
dictive of subsequent development of generalized MG as
only one of 29 patients with an abnormal SFEMG subse-
quently developed generalized MG. No patient with
normal SFEMG responded to treatment or developed gen-
eralized MG. Our findings are in concordance with
Rostedt et all retrospective study in EDC [10] and Padua’s
prospective study [7] demonstrating SFEMG in orbicularis
oculi muscle as the test of highest value in diagnosing ocu-
lar and generalized myasthenia.
Conclusion
A high diagnostic sensitivity of SFEMG in orbicularis
oculi muscle in identifying patients who are unlikely to
respond to myasthenic therapies is the most objective
diagnostic tool available to clinicians managing patients
with fluctuating ocular symptoms and negative NMJ
antibodies. The relevance of our study highlights import-
ance of SFEMG in the treatment decisions and manage-
ment of patients with ocular myasthenia.
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